Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04557956
Title Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Tazemetostat

Dabrafenib + Tazemetostat + Trametinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST